Regarding the safety measures, our study administering SGLT-2 inhibitors to end-stage renal disease patients has been designed with appropriate measures to monitor and minimize any potential health risks to the patients that participated in the study. The gene discussed is SLC5A2; the disease is stage 5 chronic kidney disease.